Mumbai, Nov. 18 -- Biocon announced that the European Commission (EC) has granted marketing authorization for Pebrilzo(R), its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU).

Published by HT Digital Content Services with permission from Capital Market....